ReviewFrontiers in cardiovascular medicine2023
Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals.
Review in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 14 citations in OpenAlex.
- Determining oncology nurses' awareness of cardio-oncology in Türkiye: A descriptive study.Asia-Pacific journal of oncology nursing · 2026Article
- The growing need for heart failure specific risk prediction models and standardized care pathways in patients with cancer.Cardio-oncology (London, England) · 2026Article
- Cardio-Oncology in Older Adults: Evidence Gaps, Geriatric Considerations, and Future Directions.Journal of clinical medicine · 2026Review
- Cardiovascular Risk Stratification and Surveillance in Cardio-Oncology: Mechanistic Foundations and Future Directions.Biomedicines · 2026Review
- ANMCO position paper E-health integration in cardiology clinical care framework.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Tyrosine kinase inhibitors - balancing the haemostatic scales: a review of associated thrombosis and bleeding.Journal of thrombosis and thrombolysis · 2026Review
- Model for bridging the gap: establishing an oncology primary care clinic for comprehensive survivorship care.Family medicine and community health · 2026Article
- Integrated Cardio-oncology Service.Cardiac failure review · 2026Review
- Prevalence and clinical risk factors of cardiovascular disease in patients with cancer: a cross-sectional study.BMC cardiovascular disorders · 2025Article
- Cardiac Metastasis: Epidemiology, Pathophysiology, and Clinical Management.Life (Basel, Switzerland) · 2025Review
- Current strategies for prevention of cancer therapy-related cardiotoxicity: pharmacological, non-pharmacological and emerging approaches.Frontiers in cardiovascular medicine · 2025Review
- Navigating the crossroads: cardiometabolic risks in cancer survivorship - a comprehensive review.Cardio-oncology (London, England) · 2024Review
- Navigating the crossroads: cardiometabolic risks in cancer survivorship - a comprehensive review.Cardio-oncology (London, England) · 2024Review
- Exploring the Perioperative Use of DOACs, off the Beaten Track.Journal of clinical medicine · 2024Review
- Cardio-oncology rehabilitation: are we ready?European heart journal supplements : journal of the European Society of Cardiology · 2024Article
- Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD).ESMO open · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
33 authors at 20 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In cancer, a patient is considered a survivor from the time of initial diagnosis until the end of life. With improvements in early diagnosis and treatment, the number of cancer survivors (CS) has grown considerably and includes: (1) Patients cured and free from cancer who may be at risk of late-onset cancer therapy-related cardiovascular toxicity (CTR-CVT); (2) Patients with long-term control of not-curable cancers in whom CTR-CVT may need to be addressed. This paper highlights the importance of the cancer care continuum, of a patient-centered approach and of a prevention-oriented policy. The ultimate goal is a personalized care of CS, achievable only through a multidisciplinary-guided survivorship care plan, one that replaces the fragmented management of current healthcare systems. Collaboration between oncologists and cardiologists is the pillar of a framework in which primary care providers and other specialists must be engaged and in which familial, social and environmental factors are also taken into account.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.